National Research Corporation (NRC), a key player in the healthcare sector, specifically within the health information services industry, is an intriguing company for investors seeking to delve into a niche market. With a market capitalization of $305.1 million, NRC offers a suite of subscription-based solutions that empower healthcare organizations with actionable insights to enhance patient and employee experiences. Headquartered in Lincoln, Nebraska, and established in 1981, NRC stands as a seasoned entity in the healthcare analytics domain.
Currently, NRC’s stock is priced at $13.39, experiencing a slight decrease of 0.03% recently. The stock has exhibited significant volatility over the past year, with a 52-week range spanning from $10.13 to $31.14. This price variability could signal opportunities for investors who can navigate its fluctuations effectively.
A standout figure in NRC’s financial profile is its exceptional Return on Equity (ROE) of 72.69%. This metric highlights the company’s impressive ability to generate returns on shareholder investments, signaling robust operational efficiency. This level of ROE is particularly notable in the healthcare sector, where managing resources effectively can be challenging due to regulatory and operational complexities.
Despite the impressive ROE, NRC’s overall performance metrics present a mixed picture. Revenue growth has dipped by 5.00%, and several key valuation metrics such as P/E Ratio, Forward P/E, and PEG Ratio remain unavailable. This lack of clarity on valuation may pose challenges for investors trying to gauge the stock’s intrinsic value. However, the company’s earnings per share (EPS) stands at 1.02, which provides some insight into its profitability.
NRC also maintains a dividend yield of 3.58%, with a payout ratio of 47.06%. This dividend yield is attractive for income-focused investors seeking regular returns, and the payout ratio indicates a balanced approach to rewarding shareholders while retaining earnings for future growth.
In terms of technical indicators, NRC’s stock is trading above its 50-day moving average of $12.79 but remains below its 200-day moving average of $17.43. The Relative Strength Index (RSI) of 3.97 suggests that the stock may be oversold, potentially indicating a buying opportunity for contrarian investors.
Interestingly, there are currently no analyst ratings available for NRC, nor is there a consensus target price. This absence of analyst coverage could suggest that the stock is flying under the radar, presenting an opportunity for investors who conduct their independent analysis.
National Research Corporation continues to innovate with offerings like the Huey AI engine, which enhances healthcare experience management. This focus on cutting-edge solutions positions NRC well to adapt to evolving market demands and maintain its relevance in a competitive industry landscape.
Investors considering NRC should weigh its high ROE and dividend yield against the backdrop of revenue contraction and the lack of comprehensive valuation metrics. This balance of factors makes NRC a compelling, albeit complex, consideration for those seeking exposure to healthcare analytics with the potential for high returns on equity.
